Pharmaceutical manufacturer and developer, Penn Pharma, has confirmed that its new contained manufacturing facility for producing highly potent products is on track for opening Q1 2013 at an exclusive event held at the British Embassy, Madrid during ICSE.
In front of an audience of industry leaders, clients, prospects and suppliers, Penn CEO, Dr Richard Yarwood announced that the 33 year old company will open the doors to its new £14 million investment in Spring 2013 and confirmed that the building is now near completion and utilities and equipment testing well underway.
The investment sees Penn Pharma expand its specialist high containment facilities with a 15,000 sq ft new development and commercial manufacturing unit for tablets and capsules meeting the highest international Quality Standards. The new facility will enable the team at Penn to further build upon its established expertise in the manufacture and packing of specialist drugs for the worldwide market.
Speaking at the British Embassy in Madrid, Richard Yarwood said: “This is the first time we have unveiled the CGI video demonstrating the full internal complexities and capabilities of the new operation. The significant investment we are making comes at a time when the established industry remodels itself and out-sourcing is on the increase.’’
Penn’s new resource provides a seamless development and manufacturing service using highly contained equipment trains installed within a purpose-built facility. The design concept uses contained processing to minimise the need for PPE (personal protective equipment) for routine operations.
Richard added: “Penn continues to go from strength to strength. Conversations held this week at ICSE and across the globe prove that there is a huge industry need for such outsourced services. This investment puts us in an excellent position to capitalise on the growth of the outsourcing industry globally.”
For more information visit www.pennpharm.com